EXACT Sciences Corp (NASDAQ:EXAS)

CAPS Rating: 2 out of 5

An applied genomics company that develops proprietary DNA-based technologies for use in the detection of cancer.

Recs

3
Player Avatar NHWeston (< 20) Submitted: 5/31/2011 9:57:20 PM : Outperform Start Price: $7.46 EXAS Score: +30.89

Exact Sciences stakes its future on a pioneering and extremely promising gambit - replacing the colonoscopy with a highly-reliable, completely non-invasive test for rectal and intestinal cancer. Its test allows for an inexpensive procedure which would mean either [1] clean bill of health without the colonoscopy ordeal or [2] a fairly specific diagnosis that would insure the need for scoptic and surgical follow-on. The tests could be done much more frequently as well. Cramer, Feuerstien, and a number of others like this stock, at least as a speculation, and it's rated a "strong buy" by others. Marketing could impede its profitability but then it also represents a natural take-over for a big pharma suffering the dyspepsia of patent expiration. I bought some.

Featured Broker Partners


Advertisement